baudax
bio
report
third
quarter
financial
results
host
conference
call
webcast
november
malvern
globe
newswire
baudax
bio
nasdaq
bxrx
pharmaceutical
company
focused
therapeutics
acute
care
settings
today
announced
report
third
quarter
financial
results
monday
november
baudax
management
team
host
conference
call
audio
webcast
et
monday
november
discuss
financial
results
recent
operational
highlights
access
conference
call
please
dial
local
international
least
minutes
prior
start
time
refer
conference
id
live
audio
webcast
call
available
events
investor
section
company
website
https
events
archived
webcast
available
company
website
approximately
two
hours
event
available
days
baudax
bio
baudax
bio
pharmaceutical
company
focused
therapeutics
acute
care
settings
launch
baudax
bio
first
commercial
product
began
june
following
approval
food
drug
administration
february
anjeso
daily
iv
nsaid
preferential
activity
successfully
completed
three
phase
iii
clinical
trials
including
two
pivotal
efficacy
trials
large
phase
iii
safety
trial
studies
management
moderate
severe
pain
addition
anjeso
baudax
pipeline
pharmaceutical
assets
including
two
novel
neuromuscular
blocking
agents
nmbas
proprietary
chemical
reversal
agent
specific
nmbas
currently
preclinical
studies
intranasal
dexmedetomidine
developed
possible
uses
pain
sedation
information
please
visit
cautionary
statement
regarding
forward
looking
statements
press
release
contains
statements
involve
risks
uncertainties
statements
reflect
baudax
bio
expectations
future
performance
opportunities
involve
substantial
risks
uncertainties
used
herein
words
anticipate
believe
estimate
may
upcoming
plan
target
goal
intend
expect
similar
expressions
relate
baudax
bio
management
intended
identify
statements
statements
based
information
available
baudax
bio
date
publication
internet
site
subject
number
risks
uncertainties
factors
could
cause
baudax
bio
performance
differ
materially
expressed
implied
statements
statements
subject
risks
uncertainties
including
among
things
ongoing
economic
social
consequences
pandemic
including
adverse
impact
commercial
launch
disruption
supply
chain
baudax
bio
ability
maintain
regulatory
approval
anjeso
baudax
bio
ability
successfully
commercialize
anjeso
acceptance
anjeso
medical
community
including
physicians
patients
health
care
providers
hospital
formularies
baudax
bio
ability
baudax
bio
third
party
manufacturers
successfully
commercial
manufacturing
process
anjeso
baudax
bio
ability
produce
commercial
supply
quantities
quality
sufficient
satisfy
market
demand
anjeso
baudax
bio
ability
raise
future
financing
continued
product
development
payment
milestones
anjeso
commercialization
baudax
bio
ability
pay
debt
satisfy
conditions
necessary
access
future
tranches
debt
baudax
bio
ability
comply
financial
covenants
credit
facility
baudax
bio
ability
manage
costs
execute
operational
budget
plans
accuracy
baudax
bio
estimates
potential
market
anjeso
baudax
bio
ability
achieve
financial
goals
baudax
bio
ability
obtain
maintain
successfully
enforce
adequate
patent
intellectual
property
protection
statements
considered
together
risks
uncertainties
may
affect
baudax
bio
business
future
results
included
filings
securities
exchange
commission
statements
based
information
currently
available
baudax
bio
baudax
bio
assume
obligation
update
statements
except
required
applicable
law
contact
investor
relations
contact
argot
partners
sam
martin
claudia
styslinger
sam
claudia
baudax
bio
ryan
lake
rlake
media
contact
argot
partners
david
rosen
